In the past five years, this top healthcare stock has risen by close to 130%.

AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with ...

AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...

AbbVie’s model fair value is held at US$253.55 per share, signaling no change to the core price target after factoring in the ...

An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.

ABBV is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of ABBV shares has decreased $1.26 since the market last closed. This is a 0.50% ...

AbbVie knows how to plan ahead.

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

AbbVie shares snapped six straight sessions of gains on Tuesday, as the stock was 1.3% lower at $251.13. The biopharmaceutical company gained 10.6% in the preceding six sessions.